Skip to content
2000
image of Exploring the Potential of Nuciferine in Diabetes Management via PTGS2 Pathway Targeting by Network Analysis and in-silico Modeling Approach

Abstract

Introduction

Diabetes mellitus, a chronic metabolic disorder characterized by elevated blood glucose levels, has emerged as a significant global health burden. Chronic inflammation and insulin resistance are central to the pathogenesis of non-insulin-dependent (type 2) diabetes mellitus. PTGS2 (prostaglandin-endoperoxide synthase 2) has been implicated in inflammatory pathways associated with diabetic complications, making it a potential therapeutic target.

Methods

Advanced computational methodologies were employed to identify potential natural compounds with anti-diabetic activity. Techniques included network pharmacology to establish compound-target-pathway relationships and molecular docking to evaluate binding affinity and interaction profiles of selected phytochemicals with PTGS2.

Results

PTGS2 and its downstream prostaglandin pathways were strongly associated with diabetic inflammation and insulin resistance. Molecular docking identified Corytuberine and Nuciferine as having high binding affinities with PTGS2. Network pharmacology analysis confirmed Nuciferine’s connection to PTGS2, supporting its role as a bioactive agent targeting diabetes-related inflammatory processes.

Discussion

The findings suggest that PTGS2 contributes to the progression of insulin resistance and chronic inflammation in type 2 diabetes. Targeting this enzyme with bioactive compounds such as Nuciferine may offer therapeutic benefits. However, translational studies and clinical trials are essential to validate these computational predictions and assess safety and efficacy .

Conclusion

Nuciferine exhibits promising potential in modulating PTGS2 activity and improving insulin sensitivity. Continued research and clinical validation are needed to confirm its efficacy and support the development of novel anti-diabetic therapies targeting inflammatory pathways.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673382481250908210052
2025-09-26
2025-11-05

  • From This Site

    /content/journals/cmc/10.2174/0109298673382481250908210052
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Ikegami H. Hiromine Y. Noso S. Insulin‐dependent diabetes mellitus in older adults: Current status and future prospects. Geriatr. Gerontol. Int. 2022 22 8 549 553 10.1111/ggi.14414 35711119
    [Google Scholar]
  2. Nikoonezhad M. Lasemi M.V. Alamdari S. Mohammadian M. Tabarraee M. Ghadyani M. Hamidpour M. Roshandel E. Treatment of insulin-dependent diabetes by hematopoietic stem cell transplantation. Transpl. Immunol. 2022 75 101682 10.1016/j.trim.2022.101682 35926800
    [Google Scholar]
  3. Tatovic D. Narendran P. Dayan C.M. Author correction: A perspective on treating type 1 diabetes mellitus before insulin is needed. Nat. Rev. Endocrinol. 2023 19 6 371 10.1038/s41574‑023‑00837‑0 36914759
    [Google Scholar]
  4. Khan M.A.B. Hashim M.J. King J.K. Govender R.D. Mustafa H. Al Kaabi J. Epidemiology of type 2 diabetes – global burden of disease and forecasted trends. J. Epidemiol. Glob. Health 2019 10 1 107 111 10.2991/jegh.k.191028.001 32175717
    [Google Scholar]
  5. Jena B.N. Kalra S. Yeravdekar R. Emotional and psychological needs of people with diabetes. Indian J. Endocrinol. Metab. 2018 22 5 696 704 10.4103/ijem.IJEM_579_17 30294583
    [Google Scholar]
  6. Gopisetty D. Levine B. Liu N. Younge P. Brown A. Close K.L. Wood R. How does diabetes affect daily life? A beyond-A1C perspective on unmet needs. Clin. Diabetes 2018 36 2 133 137 10.2337/cd17‑0093 29686452
    [Google Scholar]
  7. Ganasegeran K. Hor C.P. Jamil M.F.A. Loh H.C. Noor J.M. Hamid N.A. Suppiah P.D. Abdul Manaf M.R. Ch’ng A.S.H. Looi I. A Systematic review of the economic burden of type 2 diabetes in Malaysia. Int. J. Environ. Res. Public Health 2020 17 16 5723 10.3390/ijerph17165723 32784771
    [Google Scholar]
  8. Oberoi S. Kansra P. Economic menace of diabetes in India: A systematic review. Int. J. Diabetes Dev. Ctries. 2020 40 4 464 475 10.1007/s13410‑020‑00838‑z 32837090
    [Google Scholar]
  9. Shi L. Fonseca V. Childs B. Economic burden of diabetes-related hypoglycemia on patients, payors, and employers. J. Diabetes Complications 2021 35 6 107916 10.1016/j.jdiacomp.2021.107916 33836965
    [Google Scholar]
  10. McCall A.L. Farhy L.S. Treating type 1 diabetes: From strategies for insulin delivery to dual hormonal control. Minerva Endocrinol. 2013 38 2 145 163 23732369
    [Google Scholar]
  11. Shah R. Shah V.N. Patel M. Maahs D.M. Insulin delivery methods: Past, present and future. Int. J. Pharm. Investig. 2016 6 1 1 9 10.4103/2230‑973X.176456 27014614
    [Google Scholar]
  12. Veeresham C. Natural products derived from plants as a source of drugs. J. Adv. Pharm. Technol. Res. 2012 3 4 200 201 10.4103/2231‑4040.104709 23378939
    [Google Scholar]
  13. Liu J. Li T. Zhong G. Pan Y. Gao M. Su S. Liang Y. Ma C. Liu Y. Wang Q. Shi Q. Exploring the therapeutic potential of natural compounds for Alzheimer’s disease: Mechanisms of action and pharmacological properties. Biomed. Pharmacother. 2023 166 115406 10.1016/j.biopha.2023.115406 37659206
    [Google Scholar]
  14. Kim Y. Keogh J. Clifton P. Polyphenols and glycemic control. Nutrients 2016 8 1 17 10.3390/nu8010017 26742071
    [Google Scholar]
  15. Shahwan M. Alhumaydhi F. Ashraf G.M. Hasan P.M.Z. Shamsi A. Role of polyphenols in combating Type 2 Diabetes and insulin resistance. Int. J. Biol. Macromol. 2022 206 567 579 10.1016/j.ijbiomac.2022.03.004 35247420
    [Google Scholar]
  16. Zhang X. Jiang L. Chen H. Wei S. Yao K. Sun X. Yang G. Jiang L. Zhang C. Wang N. Wang Y. Liu X. Resveratrol protected acrolein-induced ferroptosis and insulin secretion dysfunction via ER-stress- related PERK pathway in MIN6 cells. Toxicology 2022 465 153048 10.1016/j.tox.2021.153048 34813903
    [Google Scholar]
  17. Yanagimoto A. Matsui Y. Yamaguchi T. Hibi M. Kobayashi S. Osaki N. Effects of ingesting both catechins and chlorogenic acids on glucose, incretin, and insulin sensitivity in healthy men: A randomized, double-blinded, placebo-controlled crossover trial. Nutrients 2022 14 23 5063 10.3390/nu14235063 36501092
    [Google Scholar]
  18. Hu K. Huang H. Li H. Wei Y. Yao C. Legume-derived bioactive peptides in type 2 diabetes: Opportunities and challenges. Nutrients 2023 15 5 1096 10.3390/nu15051096 36904097
    [Google Scholar]
  19. Craig S.L. Irwin N. Gault V.A. Xenin and related peptides: Potential therapeutic role in diabetes and related metabolic disorders. Clin. Med. Insights Endocrinol. Diabetes 2021 14 11795514211043868 10.1177/11795514211043868 34588834
    [Google Scholar]
  20. Zhao L. Zhang H. Li N. Chen J. Xu H. Wang Y. Liang Q. Network pharmacology, a promising approach to reveal the pharmacology mechanism of Chinese medicine formula. J. Ethnopharmacol. 2023 309 116306 10.1016/j.jep.2023.116306 36858276
    [Google Scholar]
  21. Wang X. Duan W. Lin G. Li B. Chen M. Lei F. Synthesis, 3D-QSAR and molecular docking study of nopol-based 1,2,4-triazole-thioether compounds as potential antifungal agents. Front Chem. 2021 9 757584 10.3389/fchem.2021.757584 34765587
    [Google Scholar]
  22. Abdul-Hammed M. Adedotun I.O. Olajide M. Irabor C.O. Afolabi T.I. Gbadebo I.O. Rhyman L. Ramasami P. Virtual screening, ADMET profiling, PASS prediction, and bioactivity studies of potential inhibitory roles of alkaloids, phytosterols, and flavonoids against COVID-19 main protease (M pro ). Nat. Prod. Res. 2022 36 12 3110 3116 10.1080/14786419.2021.1935933 34107799
    [Google Scholar]
  23. Alomari F.Y. Sharfalddin A.A. Abdellattif M.H. Domyati D. Basaleh A.S. Hussien M.A. QSAR modeling, molecular docking and cytotoxic evaluation for novel oxidovanadium(iv) complexes as colon anticancer agents. Molecules 2022 27 3 649 10.3390/molecules27030649 35163913
    [Google Scholar]
  24. Siva Kumar B. Anuragh S. Kammala A.K. Ilango K. Computer aided drug design approach to screen phytoconstituents of Adhatoda vasica as potential inhibitors of SARS-CoV-2 main protease enzyme. Life 2022 12 2 315 10.3390/life12020315 35207602
    [Google Scholar]
  25. Cui Q. Zhang Y. Ma Y. Yu H. Zhao X. Zhang L. Ge S. Zhang G. Qin X. A network pharmacology approach to investigate the mechanism of Shuxuening injection in the treatment of ischemic stroke. J. Ethnopharmacol. 2020 257 112891 10.1016/j.jep.2020.112891 32315738
    [Google Scholar]
  26. Zhu Y. Yu J. Zhang K. Feng Y. Guo K. Sun L. Ruan S. Network pharmacology analysis to explore the pharmacological mechanism of effective chinese medicines in treating metastatic colorectal cancer using meta-analysis approach. Am. J. Chin. Med. 2021 49 8 1839 1870 10.1142/S0192415X21500877 34781857
    [Google Scholar]
  27. Zu G. Sun K. Li L. Zu X. Han T. Huang H. Mechanism of quercetin therapeutic targets for Alzheimer disease and type 2 diabetes mellitus. Sci. Rep. 2021 11 1 22959 10.1038/s41598‑021‑02248‑5 34824300
    [Google Scholar]
  28. Chen G.Y. Wang Y.F. Yu X.B. Liu X.Y. Chen J.Q. Luo J. Tao Q.W. Network pharmacology-based strategy to investigate the mechanisms of Cibotium barometz in treating osteoarthritis. Evid. Based Complement. Alternat. Med. 2022 2022 1 15 10.1155/2022/1826299 35873632
    [Google Scholar]
  29. Niu B. Xie X. Xiong X. Jiang J. Network pharmacology-based analysis of the anti-hyperglycemic active ingredients of roselle and experimental validation. Comput. Biol. Med. 2022 141 104636 10.1016/j.compbiomed.2021.104636 34809966
    [Google Scholar]
  30. Chen L. Zhang Y.H. Wang S. Zhang Y. Huang T. Cai Y.D. Prediction and analysis of essential genes using the enrichments of gene ontology and KEGG pathways. PLoS One 2017 12 9 e0184129 10.1371/journal.pone.0184129 28873455
    [Google Scholar]
  31. Rapuru R. Begum R. F. Singh S. A. Vellapandian C. Ali N. AlAsmari A. F. Prajapati B. G. Exploring the therapeutic potential of leriodenine and nuciferine from Nelumbo nucifera for renal fibrosis: an in-silico analysis. Z. Naturforsch. C 2025 10.1515/znc‑2024‑0229
    [Google Scholar]
  32. Rushendran R. Vellapandian C. Unlocking the potential of luteolin: A natural migraine management approach through network pharmacology. J. Tradit. Complement Med. 2024 14 611 621 10.1016/j.jtcme.2024.04.011
    [Google Scholar]
  33. AS S C Vellapandian In silicoand pharmacokinetic assessment of echinocystic acid effectiveness in Alzheimer’s disease like pathology. Futur Sci OA 2023 10 1 FSO904 10.2144/fsoa‑2023‑0150 38827791
    [Google Scholar]
  34. Begum R.F. Mohan S. Insights into vitamin E with combined oral contraceptive on INSR gene in PCOS by integrating in silico and in vivo approaches. Appl. Biochem. Biotechnol. 2023 196 6 2990 3009 10.1007/s12010‑023‑04710‑8 37610513
    [Google Scholar]
  35. Adasme M.F. Linnemann K.L. Bolz S.N. Kaiser F. Salentin S. Haupt V.J. Schroeder M. PLIP 2021: Expanding the scope of the protein–ligand interaction profiler to DNA and RNA. Nucleic Acids Res. 2021 49 W1 W530 W534 10.1093/nar/gkab294 33950214
    [Google Scholar]
  36. KOLEVA Predicting molecular properties and the bioactivity score of some compounds of dill essential oils. J. Balk. Tribol. Assoc. 2020 26 580 588
    [Google Scholar]
  37. Gregory G.A. Robinson T.I.G. Linklater S.E. Wang F. Colagiuri S. de Beaufort C. Donaghue K.C. Magliano D.J. Maniam J. Orchard T.J. Rai P. Ogle G.D. Harding J.L. Wander P.L. Zhang X. Li X. Karuranga S. Chen H. Sun H. Xie Y. Oram R. Magliano D.J. Zhou Z. Jenkins A.J. Ma R.C.W. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: A modelling study. Lancet Diabetes Endocrinol. 2022 10 10 741 760 10.1016/S2213‑8587(22)00218‑2 36113507
    [Google Scholar]
  38. Deng X. Wang P. Yuan H. Epidemiology, risk factors across the spectrum of age-related metabolic diseases. J. Trace Elem. Med. Biol. 2020 61 126497 10.1016/j.jtemb.2020.126497 32247247
    [Google Scholar]
  39. Vellapandian C. Chandran L. Singh S A. Diagnostic dilemmas and current treatment approaches in latent onset autoimmune diabetes in adults: A concise review. Curr. Diabetes Rev. 2023 19 1 e240322202561 10.2174/1573399818666220324095918 35331118
    [Google Scholar]
  40. Tremblay J. Hamet P. Environmental and genetic contributions to diabetes. Metabolism 2019 100 153952 10.1016/j.metabol.2019.153952 31610851
    [Google Scholar]
  41. Krass I. Schieback P. Dhippayom T. Adherence to diabetes medication: A systematic review. Diabet. Med. 2015 32 6 725 737 10.1111/dme.12651 25440507
    [Google Scholar]
  42. Schmidt S.K. Hemmestad L. MacDonald C.S. Langberg H. Valentiner L.S. Motivation and barriers to maintaining lifestyle changes in patients with type 2 diabetes after an intensive lifestyle intervention (the U-TURN trial): A longitudinal qualitative study. Int. J. Environ. Res. Public Health 2020 17 20 7454 10.3390/ijerph17207454 33066239
    [Google Scholar]
  43. Hanefeld M. Fleischmann H. Siegmund T. Seufert J. Rationale for timely insulin therapy in type 2 diabetes within the framework of individualised treatment: 2020 update. Diabetes Ther. 2020 11 8 1645 1666 10.1007/s13300‑020‑00855‑5 32564335
    [Google Scholar]
  44. Benninger R.K.P. Hodson D.J. New understanding of β- Cell heterogeneity and in situ islet function. Diabetes 2018 67 4 537 547 10.2337/dbi17‑0040 29559510
    [Google Scholar]
  45. Li M. Chi X. Wang Y. Setrerrahmane S. Xie W. Xu H. Trends in insulin resistance: Insights into mechanisms and therapeutic strategy. Signal Transduct. Target. Ther. 2022 7 1 216 10.1038/s41392‑022‑01073‑0 35794109
    [Google Scholar]
  46. Yoo J.H. Kim J.H. Advances in continuous glucose monitoring and integrated devices for management of diabetes with insulin-based therapy: Improvement in glycemic control. Diabetes Metab. J. 2023 47 1 27 41 10.4093/dmj.2022.0271 36635028
    [Google Scholar]
  47. Pease A. Zomer E. Liew D. Lo C. Earnest A. Zoungas S. Cost-effectiveness of health technologies in adults with type 1 diabetes: A systematic review and narrative synthesis. Syst. Rev. 2020 9 1 171 10.1186/s13643‑020‑01373‑y 32746937
    [Google Scholar]
  48. Jia G. Sowers J.R. Hypertension in diabetes: An update of basic mechanisms and clinical disease. Hypertension 2021 78 5 1197 1205 10.1161/HYPERTENSIONAHA.121.17981 34601960
    [Google Scholar]
  49. Martín-Vázquez E. Cobo-Vuilleumier N. López-Noriega L. Lorenzo P.I. Gauthier B.R. The PTGS2/COX2-PGE 2 signaling cascade in inflammation: Pro or anti? A case study with type 1 diabetes mellitus. Int. J. Biol. Sci. 2023 19 13 4157 4165 10.7150/ijbs.86492 37705740
    [Google Scholar]
  50. Zatterale F. Longo M. Naderi J. Raciti G.A. Desiderio A. Miele C. Beguinot F. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Front. Physiol. 2020 10 1607 10.3389/fphys.2019.01607 32063863
    [Google Scholar]
  51. Martin Vázquez E. Cobo-Vuilleumier N. Araujo Legido R. Marín-Cañas S. Nola E. Dorronsoro A. López Bermudo L. Crespo A. Romero-Zerbo S.Y. García-Fernández M. Martin Montalvo A. Rojas A. Comaills V. Bérmudez-Silva F.J. Gannon M. Martin F. Eizirik D. Lorenzo P.I. Gauthier B.R. NR5A2/LRH-1 regulates the PTGS2-PGE2-PTGER1 pathway contributing to pancreatic islet survival and function. iScience 2022 25 5 104345 10.1016/j.isci.2022.104345 35602948
    [Google Scholar]
  52. Khalifa A.S. Elshebiny A. Eed E.M. Elhelbawy M.G. Rizk S.K. Genetic variations of tumor necrosis factor-α and prostaglandin-endoperoxide synthase 2 genes among Egyptian patients with type 2 diabetes mellitus and diabetic nephropathy. Gene Rep. 2022 29 101678 10.1016/j.genrep.2022.101678
    [Google Scholar]
  53. Okdahl T. Wegeberg A.M. Pociot F. Brock B. Størling J. Brock C. Low-grade inflammation in type 2 diabetes: A cross-sectional study from a Danish diabetes outpatient clinic. BMJ Open 2022 12 12 e062188 10.1136/bmjopen‑2022‑062188 36517105
    [Google Scholar]
  54. Chen Q. He Y. Wang X. Zhu Y. Huang Y. Cao J. Yan R. LncRNA PTGS2 regulates islet β-cell function through the miR-146a-5p/RBP4 axis and its diagnostic value in type 2 diabetes mellitus. Am. J. Transl. Res. 2021 13 10 11316 11328 34786060
    [Google Scholar]
  55. Willcox M.L. Elugbaju C. Al-Anbaki M. Lown M. Graz B. Effectiveness of medicinal plants for glycaemic control in type 2 diabetes: An overview of meta-analyses of clinical trials. Front. Pharmacol. 2021 12 777561 10.3389/fphar.2021.777561 34899340
    [Google Scholar]
  56. Gaonkar V.P. Hullatti K. Indian Traditional medicinal plants as a source of potent Anti-diabetic agents: A Review. J. Diabetes Metab. Disord. 2020 19 2 1895 1908 10.1007/s40200‑020‑00628‑8 33553046
    [Google Scholar]
  57. Kumari S. Anmol Bhatt V. Suresh P.S. Sharma U. Cissampelos pareira L.: A review of its traditional uses, phytochemistry, and pharmacology. J. Ethnopharmacol. 2021 274 113850 10.1016/j.jep.2021.113850 33485976
    [Google Scholar]
  58. Gupta A. Kumar R. Pandey A.K. Antioxidant and antidiabetic activities of Terminalia bellirica fruit in alloxan induced diabetic rats. S. Afr. J. Bot. 2020 130 308 315 10.1016/j.sajb.2019.12.010
    [Google Scholar]
  59. Alkanad M. Hani U. v A.H. Ghazwani M. Haider N. Osmani R.A.M. M D P. Hamsalakshmi Bhat R. Bitter yet beneficial: The dual role of dietary alkaloids in managing diabetes and enhancing cognitive function. Biofactors 2024 50 4 634 673 10.1002/biof.2034 38169069
    [Google Scholar]
  60. Tang Z. Luo T. Huang P. Luo M. Zhu J. Wang X. Lin Q. He Z. Gao P. Liu S. Nuciferine administration in C57BL/6J mice with gestational diabetes mellitus induced by a high-fat diet: The improvement of glycolipid disorders and intestinal dysbacteriosis. Food Funct. 2021 12 22 11174 11189 10.1039/D1FO02714J 34636388
    [Google Scholar]
  61. Zhou T. Song G. Tian D. Liu Q. Shen J. Yang X. Zhao P. Nuciferine relieves type 2 diabetes mellitus via enhancing GLUT4 expression and translocation. Food Sci. Hum. Wellness 2023 12 6 2040 2051 10.1016/j.fshw.2023.03.020
    [Google Scholar]
/content/journals/cmc/10.2174/0109298673382481250908210052
Loading
Exploring the Potential of Nuciferine in Diabetes Management via PTGS2 Pathway Targeting by Network Analysis and in-silico Modeling Approach
Bentham Science Publishers ; https://doi.org/10.2174/0109298673382481250908210052
/content/journals/cmc/10.2174/0109298673382481250908210052
/content/journals/cmc/10.2174/0109298673382481250908210052
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: network pharmacology ; insulin resistance ; Cissampelos pareira ; Terminalia bellirica ; PTGS2 ; molecular docking

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test